Why has Big Pharma remained silent despite RFK Jr.'s accusations of fraud and conspiracy following his confirmation as HHS Secretary?

The healthcare industry's silence stems from strategic calculation rather than lack of concern. According to industry analysis, pharmaceutical companies recognize they lack the political power to prevent RFK Jr.'s confirmation and fear that vocal opposition could make them bigger targets for his promised accountability measures. By staying quiet, they hope to minimize potential retaliation and limit damage if Kennedy implements his plans to fundamentally restructure the healthcare industry. This calculated silence reflects their assessment that speaking out would be more costly than remaining under the radar. The strategy represents a defensive posture from an industry that typically wields significant political influence, suggesting they view RFK Jr.'s appointment as representing a genuine threat to established healthcare practices and regulatory frameworks.